Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patients
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2016
At a glance
- Drugs GEN 0101 (Primary) ; GEN 0101 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association (2016) .
- 25 Sep 2012 Planned end date (1 Aug 2014) as reported by University Hospital Medical Information Network - Japan.
- 23 Nov 2011 trial appears to be underway according to an AnGes MG media release